Janney Montgomery Scott LLC Has $12.70 Million Stock Holdings in Cencora, Inc. $COR

Janney Montgomery Scott LLC reduced its position in Cencora, Inc. (NYSE:COR) by 24.7% in the 1st quarter, Holdings Channel reports. The institutional investor owned 40,413 shares of the company’s stock after selling 13,237 shares during the period. Janney Montgomery Scott LLC’s holdings in Cencora were worth $12,696,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. lifted its stake in shares of Cencora by 160.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock valued at $2,262,956,000 after acquiring an additional 4,123,795 shares during the period. Norges Bank bought a new stake in Cencora during the 4th quarter worth about $822,506,000. Marshall Wace LLP raised its holdings in Cencora by 518.9% during the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after purchasing an additional 1,672,762 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Cencora by 528.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock valued at $461,250,000 after purchasing an additional 1,241,186 shares during the period. Finally, Viking Global Investors LP lifted its position in Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after purchasing an additional 1,013,913 shares during the period. Institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the subject of several analyst reports. Robert W. Baird lowered their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. William Blair initiated coverage on shares of Cencora in a report on Tuesday, April 28th. They issued a “market perform” rating on the stock. Weiss Ratings cut shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday. Morgan Stanley set a $342.00 target price on shares of Cencora in a report on Friday, May 8th. Finally, Evercore set a $360.00 target price on shares of Cencora in a research report on Wednesday, April 8th. Eleven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $367.75.

Insider Activity

In other Cencora news, Director Lauren M. Tyler bought 550 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was acquired at an average cost of $270.23 per share, with a total value of $148,626.50. Following the purchase, the director owned 4,359 shares in the company, valued at $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.38% of the company’s stock.

Cencora Stock Performance

Shares of Cencora stock opened at $288.20 on Thursday. The company has a market capitalization of $56.07 billion, a PE ratio of 22.10, a PEG ratio of 1.57 and a beta of 0.58. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The stock’s fifty day simple moving average is $278.46 and its 200 day simple moving average is $320.89.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same period in the previous year, the firm posted $4.42 earnings per share. The firm’s revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, research analysts predict that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were given a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. Cencora’s payout ratio is currently 18.40%.

Cencora declared that its board has authorized a stock buyback plan on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to buy up to 3.9% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.